MAb characterisation course could reskill small molecule API workers, NIBRT

By Dan Stanton contact

- Last updated on GMT

Ireland's National Institute for Bioprocessing Research & Training in Dublin
Ireland's National Institute for Bioprocessing Research & Training in Dublin

Related tags: Small molecule, Monoclonal antibodies

Interested in moving from small to large molecule manufacturing? An upcoming course will address mAb characterisation challenges and offer hands-on experience for small molecule manufacturers , says NIBRT, Ireland’s biomanufacturing training centre.

The course set is being run by NIBRT – Ireland’s Government-funded National Institute for Bioprocessing Research & Training – and is intended to teach those currently working in small molecule active pharmaceutical ingredient (API) quality or technical roles more about high end analytical methods for monoclonal antibody (mAb) characterisation.

“An individual with qualifications and experience in a small molecule manufacturing would have many of the key competencies required for a role in biologics manufacturing,”​ projects director Killian O’Driscoll told Biopharma-Reporter.com.

“Depending on the role they’re interested in, they would need to cross skill in key areas such understanding the biological process, cell culture, protein biochemistry, protein purification, aspectic manufacturing.”

Over the course of two days next month, participants will develop a good understanding of the differences between small and large molecule quality control testing, identify transferrable skills and be introduced to new bioanalytical techniques, O’Driscoll said.

They will also become aware of the orthogonal analytical approaches used for the characterisation of mAbs and be given introductory practical experience in the practical application of methods for large molecule characterisation using both intact protein and peptide centred analytical strategies, he added, through a curricula designed and reviewed by a panel of industry experts.

The reskilling of workers comes as Ireland, a traditional hub of small molecule manufacturing, benefits from a wealth of biopharma investment.

While O’Driscoll said the small molecule sector continues to perform well, there have been a number of plant closures announced recently, for example by Roche​ and MSD​ (known as Merck & Co. in North America).

“[But] the biologics industry in Ireland continues to grow strongly with an estimated $10bn in capital investment in the last 10 years with recent announcements from Shire​, Regeneron​, BMS​, Alexion​ among others.”

The course takes place on July 5-6 at NIBRT’s centre in Dublin.

NIBRT and Thermo Fisher

In related news, NIBRT has inked a deal to develop workflows usingThermo Fisher's biomolecule column range, liquid chromatography systems and Orbitrap high resolution mass spectrometers.

"This collaboration is important because it enables our team to access Thermo Fisher’s world leading columns and analytical instrumentation to develop total analytical solutions and streamline the characterisation of complex biopharmaceuticals,"​ said Jonathan Bones, principal investigator, NIBRT’s Characterisation and Compatibility Laboratory.

"The availability of total analytical solutions to scientists across the world is empowering and motivates us at NIBRT to continually perform excellent impactful research."

Related news

Show more

Related products

show more

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Related suppliers

Follow us

Products

View more

Webinars